Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?

Gallamini A, Kostakoglu L.

Blood. 2012 Dec 13;120(25):4913-20. doi: 10.1182/blood-2012-03-403790. Epub 2012 Aug 28.

2.

Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.

Adams HJ, Kwee TC.

Eur J Haematol. 2016 Dec;97(6):491-498. doi: 10.1111/ejh.12791. Epub 2016 Sep 14. Review.

PMID:
27528557
3.

Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?

Kostakoglu L, Gallamini A.

J Nucl Med. 2013 Jul;54(7):1082-93. doi: 10.2967/jnumed.113.120451.

4.

Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.

Okosun J, Warbey V, Shaw K, Montoto S, Fields P, Marcus R, Virchis A, McNamara C, Bower M, Cwynarski K.

AIDS. 2012 Apr 24;26(7):861-5. doi: 10.1097/QAD.0b013e32835213b1.

PMID:
22333746
5.

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.

Evens AM, Kostakoglu L.

Blood. 2014 Nov 27;124(23):3356-64. doi: 10.1182/blood-2014-05-577627. Review. Erratum in: Blood. 2015 Apr 9;125(15):2450.

6.

FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?

Hutchings M.

Hematol Oncol Clin North Am. 2014 Feb;28(1):87-103. doi: 10.1016/j.hoc.2013.10.008. Review.

PMID:
24287070
7.

Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation.

Gallamini A, Fiore F, Sorasio R, Meignan M.

Leuk Lymphoma. 2009 Nov;50(11):1761-4. doi: 10.3109/10428190903308072.

PMID:
19883305
8.

Role of PET in lymphoma.

Gallamini A, Borra A.

Curr Treat Options Oncol. 2014 Jun;15(2):248-61. doi: 10.1007/s11864-014-0278-4. Review.

PMID:
24619427
9.

Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.

Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, Chrétien ML, Bastie JN, Brunotte F, Casasnovas RO.

J Nucl Med. 2014 Apr;55(4):569-73. doi: 10.2967/jnumed.113.130609. Epub 2014 Feb 24.

10.

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.

Evens AM, Kostakoglu L.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):135-43. doi: 10.1182/asheducation-2014.1.135. Epub 2014 Nov 18. Review. Erratum in: Hematology Am Soc Hematol Educ Program. 2015;2015:652.

PMID:
25696846
11.

Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.

Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, Dedeckova K, Eich HT, Böll B, Dietlein M, Kozak T.

Leuk Lymphoma. 2012 Jan;53(1):64-70. doi: 10.3109/10428194.2011.603444. Epub 2011 Aug 24.

PMID:
21740300
12.

Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.

Le Roux PY, Gastinne T, Le Gouill S, Nowak E, Bodet-Milin C, Querellou S, Mahe B, Dubruille V, Blin N, Salaun PY, Bodere-Kraeber F.

Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1064-71. doi: 10.1007/s00259-011-1741-0. Epub 2011 Feb 10.

PMID:
21308370
13.

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR.

Ann Oncol. 2005 Jul;16(7):1160-8. Epub 2005 Jun 6.

PMID:
15939713
14.

Early interim PET scan in Hodgkin lymphoma: where do we stand?

Gallamini A, Hutchings M, Avigdor A, Polliack A.

Leuk Lymphoma. 2008 Apr;49(4):659-62. doi: 10.1080/10428190801888704. Review.

PMID:
18398732
15.

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L.

Blood. 2006 Jan 1;107(1):52-9. Epub 2005 Sep 8.

16.

18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.

Kahraman D, Theurich S, Rothe A, Kuhnert G, Sasse S, Scheid C, Dietlein M, Drzezga A, von Bergwelt-Baildon M, Kobe C.

Leuk Lymphoma. 2014 Apr;55(4):811-6. doi: 10.3109/10428194.2013.819575. Epub 2013 Jul 29.

PMID:
23805904
17.

The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.

Paolini R, Rampin L, Rodella E, Ramazzina E, Banti E, Al-Nahhas A, Rubello D.

Nucl Med Rev Cent East Eur. 2007;10(2):87-90.

PMID:
18228212
18.

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A.

J Clin Oncol. 2007 Aug 20;25(24):3746-52. Epub 2007 Jul 23.

PMID:
17646666
19.

FDG-PET imaging for Hodgkin lymphoma: current use and future applications.

Kostakoglu L, Evens AM.

Clin Adv Hematol Oncol. 2014 Jan;12(1):20-35. Review.

PMID:
25000313
20.

Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.

Adams HJ, Nievelstein RA, Kwee TC.

Br J Haematol. 2015 Aug;170(3):356-66. doi: 10.1111/bjh.13441. Epub 2015 Apr 13. Review.

PMID:
25868485

Supplemental Content

Support Center